keyword
MENU ▼
Read by QxMD icon Read
search

Taxan

keyword
https://www.readbyqxmd.com/read/28106330/separation-and-purification-of-two-taxanes-and-one-xylosyl-containing-taxane-from-taxus-wallichiana-zucc-a-comparison-between-high-speed-counter-current-chromatography-and-reversed-phase-flash-chromatography
#1
Junfei Tao, Rongwei Yan, Leilei Zhao, Dongmei Wang, Xinjun Xu
10-Deacetylbaccatin III, an important semi-synthetic precursor of paclitaxel and docetaxel, can be extracted from Taxus wallichiana Zucc.. A process for the isolation and purification of 10-deacetylbaccatin III (1), baccatin III (2) and 7β-xylosyl-10-deacetyltaxol (3) from the leaves and branches of Taxus wallichiana Zucc. via macroporous resin column chromatography combined with high-speed counter-current chromatography or reversed-phase flash chromatography was developed in this study. After fractionation by macroporous resin column chromatography, 80% methanol fraction was selected based on high-performance liquid chromatography and liquid chromatography with mass spectrometry qualitative analysis...
January 20, 2017: Journal of Separation Science
https://www.readbyqxmd.com/read/28105873/loco-regional-morbidity-after-breast-conservation-and-axillary-lymph-node-dissection-for-early-breast-cancer-with-or-without-regional-nodes-radiotherapy-perspectives-in-modern-breast-cancer-treatment-the-skagen-trial-1-is-active
#2
Hanne Melgaard Nielsen, Rasmus Blechingberg Friis, Søren Linnet, Birgitte Vrou Offersen
BACKGROUND: Axillary lymph node dissection (ALND) and adjuvant radiotherapy (RT) in early breast cancer are associated with a risk of morbidity, including lymphedema and impaired shoulder mobility. The aim of this study was to evaluate loco-regional morbidity after breast conserving surgery (BCS), ALND, taxane-based chemotherapy and whole breast irradiation (WBI) with or without regional nodes RT. MATERIAL AND METHODS: Eligible patients had BCS and ALND from 2007 to 2012 followed by adjuvant taxane-based chemotherapy and if indicated, trastuzumab and endocrine treatment...
January 20, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28104363/insights-into-the-distinct-mechanisms-of-action-of-taxane-and-non-taxane-microtubule-stabilizers-from-cryo-em-structures
#3
Elizabeth H Kellogg, Nisreen M A Hejab, Stuart Howes, Peter Northcote, John H Miller, J Fernando Díaz, Kenneth H Downing, Eva Nogales
A number of microtubule-stabilizing agents have demonstrated or predicted potential as anticancer agents, but a detailed structural basis for their mechanism of action is still lacking. We have obtained high-resolution (3.9-4.2Å) cryo-EM reconstructions of microtubules stabilized by the taxane-site binders Taxol and zampanolide, and by peloruside, which targets a distinct, non-taxoid pocket on β-tubulin. We find that each molecule has unique distinct structural effects on the microtubule lattice structure...
January 16, 2017: Journal of Molecular Biology
https://www.readbyqxmd.com/read/28104295/systematic-drug-sensitivity-testing-reveals-synergistic-growth-inhibition-by-dasatinib-or-mtor-inhibitors-with-paclitaxel-in-ovarian-granulosa-cell-tumor-cells
#4
Ulla-Maija Haltia, Noora Andersson, Bhagwan Yadav, Anniina Färkkilä, Evgeny Kulesskiy, Matti Kankainen, Jing Tang, Ralf Bützow, Annika Riska, Arto Leminen, Markku Heikinheimo, Olli Kallioniemi, Leila Unkila-Kallio, Krister Wennerberg, Tero Aittokallio, Mikko Anttonen
OBJECTIVE: Resistance to standard chemotherapy poses a major clinical problem in the treatment of ovarian cancer patients. Adult-type granulosa cell tumor (AGCT) is a unique ovarian cancer subtype for which efficient treatment options are lacking in advanced disease. To this end, systematic drug response and transcriptomics profiling were performed to uncover new therapy options for AGCTs. METHODS: The responses of three primary and four recurrent AGCTs to 230 anticancer compounds were screened in vitro using a systematic drug sensitivity and resistance testing (DSRT) platform, coupled with mRNA sequencing...
January 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28095398/aurora-b-expression-modulates-paclitaxel-response-in-non-small-cell-lung-cancer
#5
Ahmed Sk Al-Khafaji, Michael Pa Davies, Janet M Risk, Michael W Marcus, Maria Koffa, John R Gosney, Richard J Shaw, John K Field, Triantafillos Liloglou
BACKGROUND: Taxanes are mitotic poisons widely used in the treatment of non-small cell lung cancer (NSCLC), however, little is known about potential molecular modulators of response to these compounds. Aurora B (AURKB) is a critical regulator of the mitotic spindle assembly, previously shown overexpressed in NSCLC. Here we investigated the hypothesis that AURKB expression modulates the efficacy of taxanes in NSCLC cells. METHODS: AURKB mRNA expression was determined by qPCR in 132 frozen NSCLC tissues and nine NSCLC cell lines...
January 17, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28092994/current-status-and-future-prospects-of-hyperthermic-intraoperative-intraperitoneal-chemotherapy-hipec-clinical-trials-in-ovarian-cancer
#6
Renee A Cowan, Roisin E O'Cearbhaill, Oliver Zivanovic, Dennis S Chi
The natural history of advanced-stage epithelial ovarian cancer is one of clinical remission after surgery and platinum/taxane-based intravenous and/or intraperitoneal chemotherapy followed by early or late recurrence in the majority of patients. Prevention of progression and recurrence remains a major hurdle in the management of ovarian cancer. Recently, many investigators have evaluated the use of normothermic and hyperthermic intraoperative intraperitoneal drug delivery as a management strategy. This is a narrative review of the current status of clinical trials of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian cancer and the future directions for this treatment strategy...
January 16, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28089283/myc-amplification-as-a-predictive-factor-of-complete-pathologic-response-to-docetaxel-based-neoadjuvant-chemotherapy-for-breast-cancer
#7
Cynthia Brito Lins Pereira, Mariana Ferreira Leal, Eliana Saul Furquim Werneck Abdelhay, Sâmia Demachki, Paulo Pimentel Assumpção, Mirian Carvalho de Souza, Caroline Aquino Moreira-Nunes, Adriana Michiko da Silva Tanaka, Marília Cardoso Smith, Rommel Rodríguez Burbano
BACKGROUND: Neoadjuvant chemotherapy is a standard treatment for stage II and III breast cancer. The identification of biomarkers that may help in the prediction of response to neoadjuvant therapies is necessary for a more precise definition of the best drug or drug combination to induce a better response. MATERIAL AND METHODS: We assessed the role of Ki67, hormone receptors expression, HER2, MYC genes and their protein status, and KRAS codon 12 mutations as predictor factors of pathologic response to anthracycline-cyclophosphamide (AC) followed by taxane docetaxel (T) neoadjuvant chemotherapy (AC+T regimen) in 51 patients with invasive ductal breast cancer...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28087740/bone-microenvironment-changes-in-latexin-expression-promote-chemoresistance
#8
Mi Zhang, Mary Osisami, Jinlu Dai, Jill M Keller, June Escara-Wilke, Atsushi Mizokami, Evan T Keller
: Although docetaxel (DOX) is the standard of care for advanced prostate cancer (PCa), most patients develop resistance to DOX. Therefore, elucidating the mechanism that underlies resistance to DOX is critical to enhance therapeutic intervention. Mining cDNA microarray from the PC-3 PCa cell line and its DOX-resistant derivative (PC3-TxR) revealed decreased latexin (LXN) expression in the resistant cells. LXN expression was inversely correlated with taxane resistance in a panel of PCa cell lines...
January 13, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28081304/comparison-of-an-ac-taxane-versus-ac-free-regimen-and-paclitaxel-versus-docetaxel-in-patients-with-lymph-node-positive-breast-cancer-final-results-of-the-national-surgical-adjuvant-study-of-breast-cancer-02-trial-a-randomized-comparative-phase-3-study
#9
Toru Watanabe, Masaru Kuranami, Kenichi Inoue, Norikazu Masuda, Kenjiro Aogi, Shinji Ohno, Hiroji Iwata, Hirofumi Mukai, Yukari Uemura, Yasuo Ohashi
BACKGROUND: In postoperative patients with breast cancer, the combination of an anthracycline and cyclophosphamide (AC) followed by a taxane is a standard regimen. In the current study, the authors examined whether AC could be safely omitted, and compared the effectiveness of paclitaxel versus docetaxel. METHODS: Female postoperative patients with axillary lymph node-positive breast cancer were eligible for enrollment in this phase 3, open-label, randomized controlled trial at 84 centers in Japan...
January 12, 2017: Cancer
https://www.readbyqxmd.com/read/28078663/inhibition-of-hsp90-exerts-anti-tumor-effect-on-angiosarcoma-involvement-of-vegf-signaling-pathway
#10
S Yamada-Kanazawa, I Kajihara, S Fukushima, M Jinnin, M Masuzawa, M Masuzawa, Y Amoh, D Hoshina, R Abe, H Ihn
BACKGROUND: Angiosarcoma is a rare malignant neoplasm derived from endothelial cells and its prognosis is poor because advanced angiosarcoma is resistant to standard chemotherapy, and new therapies are urgently needed. Heat shock protein 90 (HSP90) has been identified as a molecular chaperone that regulates various cancer-related proteins. Numerous clinical trials are testing the effectiveness of HSP90 inhibitors in various types of malignancies. OBJECTIVES: To investigate the role of HSP90 in the pathogenesis of angiosarcoma and whether inhibition of HSP90 may have anti-tumor activity...
January 12, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28078561/clinical-benefit-of-nanoparticle-albumin-bound-paclitaxel-in-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-resistant-to-cremophor-based-paclitaxel-or-docetaxel
#11
Jessica Ley, Tanya M Wildes, Kristin Daly, Peter Oppelt, Douglas Adkins
The clinical benefit of nab-paclitaxel monotherapy for recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) that progressed on other taxanes (cremophor-based paclitaxel or docetaxel) is unknown. A retrospective analysis of patients treated at a single institution with nab-paclitaxel for taxane-resistant RM-HNSCC. The exploratory hypothesis was that nab-paclitaxel would result in clinical benefit (tumor response) in patients with taxane-resistant RM-HNSCC. Twelve patients who were treated with nab-paclitaxel monotherapy for taxane-resistant RM-HNSCC and met all eligibility criteria were identified...
February 2017: Medical Oncology
https://www.readbyqxmd.com/read/28076330/the-correlation-of-age-with-chemotherapy-induced-ovarian-function-failure-in-breast-cancer-patients
#12
Ingeborg J H Vriens, Ashley J R De Bie, Maureen J B Aarts, Maaike de Boer, Irene E G van Hellemond, Joyce H E Roijen, Ron J T van Golde, Adri C Voogd, Vivianne C G Tjan-Heijnen
PURPOSE: To assess the incidence of chemotherapy-induced ovarian function failure (COFF) based on estradiol and follicle stimulating hormone (FSH) monitoring in premenopausal women with hormone-receptor positive breast cancer treated with second and third generation (neo-)adjuvant chemotherapy. RESULTS: We identified 115 eligible women. Two years after start of chemotherapy, COFF was significantly more often present in women ≥ 40 years (85.6%) as compared to women < 40 years (8...
January 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/28075166/the-predictive-value-of-ki-67-before-neoadjuvant-chemotherapy-for-breast-cancer-a-systematic-review-and-meta-analysis
#13
Xianyu Chen, Chao He, Dongdong Han, Meirong Zhou, Quan Wang, Jinhui Tian, Lun Li, Feng Xu, Enxiang Zhou, Kehu Yang
AIM: To review the predictive values of Ki-67 before neoadjuvant chemotherapy (NAC) for breast cancer patients. METHODS: PubMed and EMBASE were searched. Random-effect model meta-analysis was conducted using Revman software. RESULTS: High Ki-67 was associated with more pathological complete responses (pCRs) events (odds ratio: 3.10; 95% CI: 2.52-3.81; 53 studies, 10,848 patients) regardless of HR(+), HER2(+) and triple-negative breast cancer types, the definitions of pCR and cut-off points for Ki-67...
January 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28071616/presenting-features-treatment-patterns-and-outcomes-of-patients-with-breast-cancer-in-pakistan-experience-at-a-university-hospital
#14
S Kumar, A J Shaikh, Y A Rashid, N Masood, Atv Mohammed, U Z Malik, G Haider, N Niamutullah, S Khan
BACKGROUND: Breast cancer is the most common cancer in Pakistani women. We report the presenting features, treatment patterns and survival of breast cancer from a University Hospital in Southern Pakistan and compare the data with international population based studies. MATERIALS AND METHODS: Medical records of patients diagnosed to have breast cancer between January 1999 and November 2008 were reviewed retrospectively. RESULTS: A total of 845 patients were identified...
April 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28071613/clinical-and-pathologic-response-following-taxane-based-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer-patients-in-a-tertiary-care-centre-in-india
#15
Masillamany Sivasanker, S C Sistla, S Ali Manwar, S Vivekanandam
BACKGROUND: Neoadjuvant chemotherapy has become the standard recommendation in the management of patients with locally advanced breast cancer. At present anthracycline based regimen such as CAF (cyclophosphamide, adriamycin and 5-FU) is widely used in clinical practice. The introduction of taxanes has revolutionized this field because of superior results. AIMS AND OBJECTIVES: This study is designed to compare the efficacy of paclitaxel plus doxorubicin regimen and CAF (cyclophosphamide, doxorubicin and 5-fluorouracil) regimen as neoadjuvant treatment of locally advanced breast cancer and to compare their toxicity profiles and also to correlate the hormonal receptor status in predicting response to the NACT...
April 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28067173/marine-derived-anticancer-drugs-targeting-microtubule
#16
Oindrila De, Biswa Prasun Chatterji
BACKGROUND: Microtubule dynamics play a vital role in regulating crucial cellular functions and are one of the most attractive anticancer drug targets. Microtubule targeting agents (MTAs) such as the vinca alkaloids or taxanes, although are effective for cancer therapy, have adverse side effects. Another hindrance in their development is multiple drug resistance in tumor cells. These drawbacks have urged the need to develop novel MTAs from alternative sources, with better therapeutic efficacy...
January 9, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28063866/chemotherapy-induced-neuropathy-in-cancer-survivors
#17
Christine Miaskowski, Judy Mastick, Steven M Paul, Kimberly Topp, Betty Smoot, Gary Abrams, Lee-May Chen, Kord M Kober, Yvette P Conley, Margaret Chesney, Kay Bolla, Grace Mausisa, Melissa Mazor, Melisa Wong, Mark Schumacher, Jon D Levine
CONTEXT: Evidence suggests that chemotherapy-induced neuropathy (CIN) is a significant problem for cancer survivors. However, a detailed phenotypic characterization of CIN in cancer survivors is not available. OBJECTIVES: To evaluate between group differences in demographic and clinical characteristics, as well as in measures of sensation, function, and postural control, in a sample of cancer survivors who received a platinum and/or a taxane-based CTX regimen and did (n=426) and did not (n=197) develop CIN...
January 4, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28063331/pcr-rates-in-patients-with-bilateral-breast-cancer-after-neoadjuvant-anthracycline-taxane-based-chemotherapy-a-retrospective-pooled-analysis-of-individual-patients-data-of-four-german-neoadjuvant-trials
#18
Mattea Reinisch, Jens Huober, Gunter von Minckwitz, Jens-Uwe Blohmer, Carsten Denkert, Claus Hanusch, Christian Jackisch, Sherko Kümmel, Andreas Schneeweiss, Kerstin Rhiem, Bianca Lederer, Michael Untch, Valentina Nekljudova V, Sibylle Loibl
PURPOSE: Patients with bilateral breast cancer (BBC) are usually excluded from participating in clinical trials and little is known about the response and outcome of BBC to neoadjuvant chemotherapy compared to unilateral BC (UBC). METHODS: We prospectively captured the information on patients with BBC in our database treated within four neoadjuvant chemotherapy trials and collected retrospectively the rate of pathological complete response (pCR) defined as ypT0 ypN0, ypT0/is ypN0, ypT0 ypNX, clinical and histologic parameters...
January 4, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28063028/her2-positive-metastatic-breast-cancer-patients-receiving-pertuzumab-in-a-community-oncology-practice-setting-treatment-patterns-and-outcomes
#19
Nicholas J Robert, Hans-Peter Goertz, Pooja Chopra, Xiaolong Jiao, Bongin Yoo, Debra Patt, Vincent Antao
BACKGROUND: Pertuzumab (Perjeta(®)), a HER2/neu receptor antagonist, was approved by the US Food and Drug Administration in June 2012 for use in the first-line setting for patients with HER2-positive metastatic breast cancer (mBC). OBJECTIVE: This retrospective study investigated the clinical and demographic characteristics, treatment patterns, safety, and clinical outcomes for patients with HER2-positive mBC who received pertuzumab in the first-line setting in US community oncology practices...
January 6, 2017: Drugs—Real World Outcomes
https://www.readbyqxmd.com/read/28061451/nanoparticle-albumin-bound-paclitaxel-as-neoadjuvant-chemotherapy-of-breast-cancer-a-systematic-review-and-meta-analysis
#20
REVIEW
Yu Zong, Jiayi Wu, Kunwei Shen
BACKGROUND: The value of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in neoadjuvant systemic therapy for breast cancer remains uncertain. METHODS: Both electronic databases and proceedings of oncologic meetings were included in systematic literature search. Pooled rates of pathological complete response (pCR), odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed-effect or random-effect model to determine the effect of neoadjuvant nab-paclitaxel...
January 3, 2017: Oncotarget
keyword
keyword
64691
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"